Dear Editor,Osimertinib yielded significantly greater efficacy than did platinum therapy plus pemetrexed in patients with T790M‐positive advanced non‐small cell lung cancer (NSCLC; including those with central nervous system metastases) in whom the disease had progressed during first‐line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKI) therapy. Just 5% of the patients discontinued osimertinib owing to an adverse effect. Among the reported deaths, the only death possibly related to treatment as reported by the investigator was as a result of interstitial lung disease. An improvement or stability of the lung cancer symptoms and functioning domains of quality of life was observed with osimertinib. Owing to the increase in the incidence of lung cancer among older individuals, the efficacy and safety of EGFR‐TKI for the treatment of older patients with NSCLC have recently garnered interest. Aging is associated with poor performance status. As osimertinib has finally been approved for clinical use, rebiopsies are often required in lung cancer patients who are positive for EGFR mutations and currently undergoing treatment.In this report, we present an advanced NSCLC patient who was unsuitable for chemotherapy because of chronic kidney disease (CKD) as a result of diabetes mellitus, and therefore was started on osimertinib at
Geriatrics & Gerontology International – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera